Who was studied, and how
Six numbers in the abstract
Where each one falls
Where it lands on the map
15,309people with type 2 diabetes, in this paper
Among patients without chronic kidney disease, the trial randomly assignedassigned by chance
canagliflozin 100 mg
placebo
Reported higher serum magnesium levels, no range given+0.06
randomisedAmong patients without chronic kidney disease, the trial randomly assignedassigned by chance
canagliflozin 300 mg
placebo
Reported higher serum magnesium levels, no range given+0.09
randomisedthe abstract, start to end
… with placebo (canagliflozin: WMD 0.06 mmol/l for 100 mg and 0.09 mmol/l for 300 mg; dapagliflozin: WMD 0.1 mmol/l for 10 mg; empagliflozin: WMD 0.04 mmol/l for 10 mg and 0.07 mmol/l for 25 mg; and ipragliflozin: WMD 0.05 mmol/l for 50 mg).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Serum magnesium levelscanagliflozin 100 mg vs placebo, in patients without chronic kidney disease
0.06
Serum magnesium levelscanagliflozin 300 mg vs placebo, in patients without chronic kidney disease
0.09
Serum magnesium levelsdapagliflozin 10 mg vs placebo, in patients without chronic kidney disease
0.1
Serum magnesium levelsempagliflozin 10 mg vs placebo, in patients without chronic kidney disease
0.04
Serum magnesium levelsempagliflozin 25 mg vs placebo, in patients without chronic kidney disease
0.07
Serum magnesium levelsipragliflozin 50 mg vs placebo, in patients without chronic kidney disease
0.05
SGLT2 inhibitorsKidney outcomes
1 / 4